Published in Eur J Endocrinol on December 01, 2007
The hypoxic testicle: physiology and pathophysiology. Oxid Med Cell Longev (2012) 1.01
Glucose homeostasis during short-term and prolonged exposure to high altitudes. Endocr Rev (2015) 0.90
Exercise training during normobaric hypoxic confinement does not alter hormonal appetite regulation. PLoS One (2014) 0.87
Influence of acute exposure to high altitude on basal and postprandial plasma levels of gastroenteropancreatic peptides. PLoS One (2012) 0.87
Effects of prolonged exposure to hypobaric hypoxia on oxidative stress, inflammation and gluco-insular regulation: the not-so-sweet price for good regulation. PLoS One (2014) 0.83
Short-term responses of the kidney to high altitude in mountain climbers. Nephrol Dial Transplant (2013) 0.81
The Effect of Normobaric Hypoxic Confinement on Metabolism, Gut Hormones, and Body Composition. Front Physiol (2016) 0.77
Kilimanjaro Abruzzo expedition: effects of high-altitude trekking on anthropometric, cardiovascular and blood biochemical parameters. Sport Sci Health (2015) 0.77
Anthropometric and hemodynamic profiles of athletes and their relevance to performance in the mount cameroon race of hope. Asian J Sports Med (2012) 0.75
Evaluation of the thickness of the proximal femoral canal in patients living at altitude. Acta Ortop Bras (2016) 0.75
Hypoxia-Related Hormonal Appetite Modulation in Humans during Rest and Exercise: Mini Review. Front Physiol (2017) 0.75
Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev (2004) 3.79
Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol (2008) 2.32
Hypopituitarism. Lancet (2007) 2.27
Investigations of thyroid hormones and antibodies in obesity: leptin levels are associated with thyroid autoimmunity independent of bioanthropometric, hormonal, and weight-related determinants. J Clin Endocrinol Metab (2010) 2.07
Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol (2002) 1.97
Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas. Hypertension (2013) 1.76
Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. JAMA (2007) 1.59
The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol (2005) 1.59
Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med (2014) 1.49
Endocrine function is altered in chronic migraine patients with medication-overuse. Headache (2006) 1.47
Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J Clin Endocrinol Metab (2002) 1.45
Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J Clin Endocrinol Metab (2004) 1.39
Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways. FASEB J (2004) 1.32
Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study. J Clin Endocrinol Metab (2005) 1.32
Extracellular vesicles as an emerging mechanism of cell-to-cell communication. Endocrine (2012) 1.32
Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury. Clin Endocrinol (Oxf) (2004) 1.29
Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart. Cardiovasc Res (2009) 1.26
Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab (2012) 1.24
Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol (2002) 1.24
Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function. Diabetes (2007) 1.22
The endocrine response to ghrelin as a function of gender in humans in young and elderly subjects. J Clin Endocrinol Metab (2003) 1.12
Unraveling the role of the ghrelin gene peptides in the endocrine pancreas. J Mol Endocrinol (2010) 1.09
Atlas of the muscle motor points for the lower limb: implications for electrical stimulation procedures and electrode positioning. Eur J Appl Physiol (2011) 1.06
Ghrelin, obesity and diabetes. Nat Clin Pract Endocrinol Metab (2007) 1.06
Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions. Am J Physiol Endocrinol Metab (2007) 1.06
Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. Eur J Endocrinol (2004) 1.05
Effect of food restriction on ghrelin in normal-cycling female rats and in pregnancy. Obes Res (2002) 1.04
Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations. Nutr Metab Cardiovasc Dis (2005) 1.03
Cardiovascular actions of the ghrelin gene-derived peptides and growth hormone-releasing hormone. Exp Biol Med (Maywood) (2011) 1.02
The IGF system. Acta Diabetol (2010) 1.01
Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. Eur J Pharmacol (2004) 1.01
Neuroendocrine alterations in obese patients with sleep apnea syndrome. Int J Endocrinol (2010) 1.01
Obstructive sleep apnoea syndrome impairs insulin sensitivity independently of anthropometric variables. Clin Endocrinol (Oxf) (2003) 1.01
Mean platelet volume is not associated with platelet reactivity and the extent of coronary artery disease in diabetic patients. Blood Coagul Fibrinolysis (2013) 1.01
Effects of acute administration of acylated and unacylated ghrelin on glucose and insulin concentrations in morbidly obese subjects without overt diabetes. Eur J Endocrinol (2009) 1.00
Unacylated ghrelin is active on the INS-1E rat insulinoma cell line independently of the growth hormone secretagogue receptor type 1a and the corticotropin releasing factor 2 receptor. Mol Cell Endocrinol (2006) 0.99
Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin. Eur J Pharmacol (2003) 0.98
Alprazolam (a benzodiazepine activating GABA receptor) reduces the neuroendocrine responses to insulin-induced hypoglycaemia in humans. Clin Endocrinol (Oxf) (2003) 0.97
Proliferative and protective effects of growth hormone secretagogues on adult rat hippocampal progenitor cells. Endocrinology (2008) 0.96
Ghrelin secretion in childhood is refractory to the inhibitory effect of feeding. J Clin Endocrinol Metab (2004) 0.95
Unacylated ghrelin rescues endothelial progenitor cell function in individuals with type 2 diabetes. Diabetes (2010) 0.95
Pituitary dysfunction after traumatic brain injury: a clinical and pathophysiological approach. Endocr Rev (2015) 0.95
Cut-off limits of the GH response to GHRH plus arginine test and IGF-I levels for the diagnosis of GH deficiency in late adolescents and young adults. Eur J Endocrinol (2007) 0.94
Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J Clin Endocrinol Metab (2014) 0.94
Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes (2012) 0.94
Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission. Clin Endocrinol (Oxf) (2011) 0.93
A reappraisal of diagnosing GH deficiency in adults: role of gender, age, waist circumference, and body mass index. J Clin Endocrinol Metab (2009) 0.93
The antiproliferative effect of synthetic peptidyl GH secretagogues in human CALU-1 lung carcinoma cells. Endocrinology (2002) 0.93
Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms. Endocrinology (2007) 0.92
Heterogeneity of ghrelin/growth hormone secretagogue receptors. Toward the understanding of the molecular identity of novel ghrelin/GHS receptors. Neuroendocrinology (2007) 0.92
Ghrelin secretion is inhibited by glucose load and insulin-induced hypoglycaemia but unaffected by glucagon and arginine in humans. Clin Endocrinol (Oxf) (2004) 0.92
High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol (2009) 0.91
Obestatin regulates adipocyte function and protects against diet-induced insulin resistance and inflammation. FASEB J (2012) 0.91
Altered glucose metabolism rather than naive type 2 diabetes mellitus (T2DM) is related to vitamin D status in severe obesity. Cardiovasc Diabetol (2014) 0.90
Association of craniopharyngioma and pituitary adenoma. Endocrine (2013) 0.88
Unacylated ghrelin and obestatin increase islet cell mass and prevent diabetes in streptozotocin-treated newborn rats. J Mol Endocrinol (2010) 0.88
Ghrelin drives GH secretion during fasting in man. Eur J Endocrinol (2002) 0.88
Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans. J Clin Endocrinol Metab (2002) 0.88
GH-releasing hormone induces cardioprotection in isolated male rat heart via activation of RISK and SAFE pathways. Endocrinology (2013) 0.88
Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab (2003) 0.88
Acylated ghrelin inhibits spontaneous luteinizing hormone pulsatility and responsiveness to naloxone but not that to gonadotropin-releasing hormone in young men: evidence for a central inhibitory action of ghrelin on the gonadal axis. J Clin Endocrinol Metab (2008) 0.87
Ghrelin in fetal thyroid and follicular tumors and cell lines: expression and effects on tumor growth. Am J Pathol (2003) 0.87
Corticotrope hypersecretion coupled with cortisol hypo-responsiveness to stimuli is present in patients with autoimmune endocrine diseases: evidence for subclinical primary hypoadrenalism? Eur J Endocrinol (2006) 0.87
Varicocele sclerotherapy improves serum inhibin B levels and seminal parameters. Int J Androl (2007) 0.87
Short ghrelin peptides neither displace ghrelin binding in vitro nor stimulate GH release in vivo. Endocrinology (2002) 0.87
Ghrelin, hypothalamus-pituitary-adrenal (HPA) axis and Cushing's syndrome. Pituitary (2004) 0.87
Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement. Eur J Endocrinol (2005) 0.86
Effect of acute and prolonged mineralocorticoid receptor blockade on spontaneous and stimulated hypothalamic-pituitary-adrenal axis in humans. Eur J Endocrinol (2010) 0.86
The nutritional control of ghrelin secretion in humans: the effects of enteral vs. parenteral nutrition. Eur J Nutr (2006) 0.86
Unacylated ghrelin promotes skeletal muscle regeneration following hindlimb ischemia via SOD-2-mediated miR-221/222 expression. J Am Heart Assoc (2013) 0.86
Insulin sensitivity in Turner's syndrome: influence of GH treatment. Eur J Endocrinol (2004) 0.85
The GH-releasing effect of ghrelin, a natural GH secretagogue, is only blunted by the infusion of exogenous somatostatin in humans. Clin Endocrinol (Oxf) (2002) 0.85
GPR103b functions in the peripheral regulation of adipogenesis. Mol Endocrinol (2010) 0.85
Acylated ghrelin as a provocative test for the diagnosis of GH deficiency in adults. Eur J Endocrinol (2012) 0.85
Ghrelin and anterior pituitary function. Front Horm Res (2010) 0.85